NTRK2 and neoplasm: The Foundation Medicine analysis utilized targeted exome sequencing deploying intron baiting for all coding exons of NTRK1,2,3 with additional baits for introns 7-11 and 13 of NTRK1 and intron 12 of NTRK2. For a tumor fraction specimen of >20%, intron baiting was reported to have a sensitivity of 100% and a positive predictive value of >98% [11].